6885 — BRIM Biotechnology Income Statement
0.000.00%
Last trade - 00:00- TWD4.37bn
- TWD2.71bn
- TWD0.02m
Annual income statement for BRIM Biotechnology, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 90.8 | 0.36 | 0.526 | 0.09 | 0.022 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 246 | 93.6 | 219 | 694 | 345 |
| Operating Profit | -155 | -93.2 | -218 | -694 | -345 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -97 | -105 | -274 | -688 | -315 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -106 | -105 | -274 | -688 | -315 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -87.9 | -105 | -274 | -688 | -315 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -87.9 | -105 | -274 | -688 | -315 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.52 | -1.34 | -3.7 | -6.84 | -2.7 |
| Dividends per Share |